Edgewise Therapeutics, a CureDuchenne funded company, today announced positive long-term Sevasemten data that demonstrated sustained functional stabilization in Becker Muscular Dystrophy (BMD) patients through 3.5 years of treatment. This result is in stark contrast to the functional decline expected from BMD natural history data.
Today’s result is particularly important for BMD patients, an underserved population, who have no approved treatment options and face significant declines in function on an annual basis.
Edgewise expects to announce top-line results of the sevasemten placebo-controlled pivotal cohort, GRAND CANYON, in 4Q 2026.
The post Edgewise Therapeutics, a CureDuchenne funded company, announces positive long-term Sevasemten data in Becker muscular dystrophy patients. appeared first on CureDuchenne.